KVISTGAARD, Denmark I February 21, 2014 I Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that its MVA-BN vaccine platform technology has been selected by the Defense Threat Reduction Agency (DTRA), a part of the United States Department of Defense, for the development of a vaccine against two potential biological threats to national security – Burkholderia pseudomallei and Burkholderia mallei.

“The award of this contract illustrates the strength of our MVA-BN vaccine platform technology, which has been developed through a decade-long partnership with the U.S. Department of Health and Human Services,” said Anders Hedegaard, President and CEO of Bavarian Nordic. “As part of our strategy to expand our biodefense business beyond smallpox, we are pleased to add DTRA to our list of government partners with whom we work to develop novel biodefense vaccines.”

DTRA is the fourth U.S. Government agency to collaborate with Bavarian Nordic on the development of novel biodefense vaccines. Other ongoing collaborations include the development of vaccines against smallpox, filoviruses (Ebola and Marburg) and foot-and-mouth disease, for which the company has received funding from the Biomedical Advanced Research and Development Authority, the National Institute of Allergy and Infectious Diseases, and the Department of Homeland Security’s Science and Technology Directorate.

Under this new USD 0.5 million contract Bavarian Nordic will design, generate and test MVA-BN-based recombinant vaccines against Burkholderia. If the contract yields a successful proof of concept, DTRA may support further development of the vaccine through a larger contract award.

Asger Aamund
Chairman of the Board

Anders Hedegaard, President & CEO. Phone +45 23 20 30 64
Paul Chaplin, President, Infectious Diseases Division. Phone 202-288-9220

About Burkholderia
Burkholderia pseudomallei and Burkholderia mallei are bacterial pathogens that have been determined to pose a material threat sufficient to affect the United States’ national security. B. pseudomallei causes melioidosis, a human disease endemic in Southeast Asia and northern Australia. B. mallei causes glanders, a zoonotic disease primarily occurring in Africa, Asia, the Middle East, and Central/South America. Because of the lengthy antibiotic therapy required to treat melioidosis and glanders, the suboptimal clinical outcomes, possible biothreat applications, and public health implications, there is significant interest in developing new vaccines capable of protecting against these agents, for which effective vaccines do not currently exist.

About MVA-BN Platform Technology
MVA-BN (Modified Vaccinia Ankara – Bavarian Nordic) is a robust and adaptable vaccine platform suitable for addressing a wide variety of infectious diseases. In addition to developing MVA-BN as a safer smallpox vaccine essential to protecting the immune-compromised population, Bavarian Nordic has conducted preclinical and clinical studies of recombinant MVA-BN-based vaccines for a variety of infectious diseases and numerous types of cancer. More than 7,300 individuals, nearly 1,000 of whom are immunocompromised, have been vaccinated with MVA-BN-based vaccines, showing the platform displays high immunogenicity and a favorable safety profile.

About Bavarian Nordic
Bavarian Nordic is an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Lead product candidates are PROSTVAC®, an immunotherapy product candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 clinical trial and IMVAMUNE®, a non-replicating smallpox vaccine candidate in Phase 3 development, which is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. The vaccine is approved in Canada under the trade name IMVAMUNE and in the European Union under the trade name IMVANEX®.

SOURCE: Bavarian Nordic